
Morepen Laboratories Q2 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 2
Fundraise
Yes
Order
Yes
Capex
Yes
3 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 3- Morepen Laboratories is projecting continued strong growth with expected revenues surpassing Rs.1,500-1,600 crores for the full year, based on H1 performance of Rs. 788 crores.
- The company reports a consistent CAGR of 25% in revenues over years, maintaining 31% growth in the first half of the current year.
- Business segments like Medical Devices and finished dosages are rapidly growing; medical devices division grew 36% in the latest quarter, and finished dosages bounced back with 28% growth.
- Positive growth in API business (9% current year growth), with capacity expansion plans underway to meet growing demand.
- Dr. Morepen OTC brand has grown 22% and online sales for grooming and lifestyle products have surged, e.g., grooming products up 51% and online product sales up 243%.
- Glucometers and BP monitors show robust growth (45% and 44% quarterly growth respectively), with increasing installed customer base driving recurring strip sales.
- Overall, Morepen expects sustainable double-digit volume and revenue growth across segments.
See what Morepen Laboratories management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Morepen Laboratories is evaluating ways to unlock value and raise capital for different divisions, including Medical Devices and API businesses.
- The Medical Devices division plans to raise fresh capital, possibly through separate investment bankers; timing for any public issue or IPO is undecided and currently kept confidential.
- The API business has large expansion plans involving capacity increase but financial closure for this expansion has not yet been done; internal accruals are currently funding growth and working capital.
- There was a prior discussion with Corinth regarding funding, but that deal was declined; potential further discussions might happen with Corinth’s unlisted companies, not the main listed entity.
- Banks are showing positive responses for converting pending preference shares into equity (around 1-2% of equity) without cash outflow, subject to approvals.
- Overall, fundraising is under consideration but no firm finalized plans or timelines for new equity or debt issuance have been announced.
See what Morepen Laboratories management said on order book — free account, 30 seconds.
Capex plans
Yes- API capacity expansion: Current 310 KL capacity being increased to 1,000 KL within 24 months at the existing site, with plans to further scale up to 5,000 KL requiring additional land nearby (pending financial closure).
- Medical Devices: Setting up a new plant on an allocated 60-acre parcel; the division will operate independently and may seek fresh capital through investment bankers.
- ANDA Facility: Setting up own facility in Baddi for ANDA filings focused on global markets; hiring underway, pilot work continuing, first ANDA filing expected in 9-12 months.
- Preference Share Conversion: Approx. 58% banker consent received to convert preference shares into equity (no cash outflow), expected before year-end.
- Divisional Structuring: Exploring independent structures and potential capital raising for Devices, API, and Finished Dosages businesses.
- Vaccine Fill-and-Finish: Facilities approved; awaiting government inspection and license for possible scaling based on partner vaccine production.
Track Morepen Laboratories — get its next earnings analysis in your feed
How does Morepen Laboratories rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Morepen Laboratories rank in Pharmaceuticals & Biotechnology?
Compare Morepen Laboratories against every Pharmaceuticals & Biotechnology company (Q2 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Morepen Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem